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Abstract
Background: Alzheimer’s disease (AD) is the most frequently diagnosed neurodegenerative disorder affecting
humans, with advanced age being the most prominent risk factor for developing AD. Despite intense research
efforts aimed at elucidating the precise molecular underpinnings of AD, a definitive answer is still lacking. In recent
years, consensus has grown that dimerisation of the polypeptide amyloid-beta (Aß), particularly Aß42, plays a crucial
role in the neuropathology that characterise AD-affected post-mortem brains, including the large-scale
accumulation of fibrils, also referred to as senile plaques. This has led to the realistic hope that targeting Aß42
immunotherapeutically could drastically reduce plaque burden in the ageing brain, thus delaying AD onset or
symptom progression. Stochastic modelling is a useful tool for increasing understanding of the processes
underlying complex systems-affecting disorders such as AD, providing a rapid and inexpensive strategy for testing
putative new therapies. In light of the tool’s utility, we developed computer simulation models to examine Aß42
turnover and its aggregation in detail and to test the effect of immunization against Aß dimers.
Results: Our model demonstrates for the first time that even a slight decrease in the clearance rate of Aß42
monomers is sufficient to increase the chance of dimers forming, which could act as instigators of protofibril and
fibril formation, resulting in increased plaque levels. As the process is slow and levels of Aβ are normally low,
stochastic effects are important. Our model predicts that reducing the rate of dimerisation leads to a significant
reduction in plaque levels and delays onset of plaque formation. The model was used to test the effect of an
antibody mediated immunological response. Our results showed that plaque levels were reduced compared to
conditions where antibodies are not present.
Conclusion: Our model supports the current thinking that levels of dimers are important in initiating the
aggregation process. Although substantial knowledge exists regarding the process, no therapeutic intervention is
on offer that reliably decreases disease burden in AD patients. Computer modelling could serve as one of a
number of tools to examine both the validity of reliable biomarkers and aid the discovery of successful intervention
strategies.
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Background
Alzheimer’s disease (AD) is characterised by cholinergic
neuron loss, synaptic dysfunction and the accumulation
of protein aggregates in specific regions of the brain [1].
The main brain regions affected are the cortex and
hippocampus leading to clinical symptoms including the
inability to form new memories and altered personality
[2,3]. Although the underlying molecular causes remain
unresolved, two functionally different proteins are
involved in the aggregation process: amyloid-beta (Aβ),
which forms extracellular plaques, and the microtubule
binding protein tau, the main component of neurofibril-
lary tangles, with the relative contribution of each to the
manifestation of disease symptoms remaining a matter
of considerable controversy [4-6]. The order of events in
the disease process is also unclear. Aβ is produced by
the sequential processing of the amyloid precursor pro-
tein (APP), by means of a catalytic process involving the
β- and γ-secretase enzymes. The Aβ peptide contains
36–43 amino acids with the actual length affecting its
properties. For example, the isoform Aβ40 is normally
secreted and less cytotoxic than Aβ42, which has a strong
tendency to aggregate in the brain and associates with
AD [7]. Levels of Aβ40 and Aβ42 also increase in normal
ageing [8] and have been shown to be elevated in the
brains of Down’s syndrome patients [9]. An association
has been made between the underlying genetic-
molecular profile of AD and that of Down’s, with the de-
tection of overexpressed APP, located on chromosome
21 [10]. Henceforth, elevated plasma concentrations of
Aβ40 and Aβ42 were regarded as prominent risk factors
for the onset of dementia in persons suffering from
Down’s syndrome [11].
The aggregation process begins with the formation of
soluble dimers and larger oligomers (e.g. tetramers and
octamers) which interact to form protofibrils [12]. Proto-
fibrils can be defined as transient structures which are
observed during the lag phase of amyloid growth. They
may disaggregate but can also grow by the addition of
soluble Aβ, to finally form insoluble fibrils and plaques
[13] (Figure 1). The issue concerning the relative contri-
bution made by monomers, dimers, oligomers, protofi-
brils, fibrils and plaques to cell toxicity and the eventual
onset of AD symptoms has elicited considerable debate
[14]. It has been suggested that dimers, oligomers and
protofibrils are more toxic than plaques [15]. In this re-
gard, it was recently suggested that Aβ dimers are par-
ticularly toxic based on evidence that they are capable of
blocking Long-Term Potentiation (LTP [16]. In this re-
gard, Shankar and colleagues found that soluble forms
of Aβ correlated best with AD compared to other forms
of dementia [16]. In another study, Rowan and co-
workers showed that human cerebrospinal fluid (CSF)
containing Aβ dimers inhibited LTP in vivo but that the
inhibition of LTP did not occur if CSF samples con-
tained only monomers [17]. This study also showed that
systemic passive immunization prevented LTP inhibition
by dimers. Clinical evidence for the role of dimers in the
disease state comes from the Cognitive Function and
Ageing Studies (CFAS) which show that the sodium
dodecyl sulfate (SDS)-stable soluble Aβ dimers found in
the temporal and frontal cortex are strongly associated
with AD [18]. In addition, it has been shown that dimers
rapidly form protofibrils giving further support to the
idea that dimers are the main building blocks of Aβ as-
semblies [19]. The growing recognition of the import-
ance of dimers in the aggregation process has led to the
development and testing of antibodies directed against
dimers. For example, a monoclonal antibody that specif-
ically recognises pathogenic forms of dimers has recently
been shown to neutralise synaptotoxic effects in rats
injected with Aβ dimers and monomers [20]. Aβ mono-
mers are usually cleared from the cell by various
mechanisms to prevent protein aggregation. Clearance
mechanisms include degradation by proteases such as
neprilysin and insulin-degrading enzyme (IDE) and
transport away from the brain via the vascular system
[21]. However, amyloid plaques do accumulate in the
brain with age and are particularly associated with AD,
suggesting impairment in the homeostatic control of for-
mation versus clearance of Aβ. Mawuenyega and collea-
gues [22] measured the production and clearance of Aβ
(both Aβ40 and Aβ42) in the CSF of AD patients com-
pared to age-matched, neurologically-intact controls.
Their study showed that the production rate of Aβ is the
same in AD as in controls, but detected a slower degrad-
ation rate in AD. This suggests that Aβ degradation kin-
etics may be impaired in AD. The mechanisms
underlying this alteration remain unknown. However,
protein levels of neprilysin, a neutral endopeptidase, and
one of the major Aβ-degrading enzymes located in the
brain, have been shown to decline with age [23,24]. This
may be attributable to oxidative damage since an in-
crease in oxidatively-damaged neprilysin was found in
AD subjects compared to normal controls [25]. Other
studies have shown that the activity of neprilsyin
increases with age in the normal brain [26] and in AD
[27], although the latter study showed decreased neprily-
sin levels with age in AD subjects. The potential for tar-
geting Aβ-degrading enzymes has been recently
reviewed [28] and motivated the inclusion of neprilysin
in our model.
The molecular mechanisms involved in AD are there-
fore complex and as yet we lack clear understanding of
which part of the aggregation process would provide the
best target for stopping or slowing down AD-related dis-
ease processes. In such complex scenarios where it has
proved difficult to disentangle the contributing disease
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processes, mathematical modelling is increasingly being
used to complement experimental approaches [29-32].
For instance, modelling can be used to integrate multiple
mechanisms, refine complex hypotheses, make testable
predictions and explore in silico the possible effective-
ness of interventions. We have used dynamic modelling
which means that the model can be used to examine
mechanisms leading to the disease state. This has an ad-
vantage over experimental approaches which are often
limited to the end time-point of the disease. Many bio-
logical processes are inherently stochastic. For example,
protein aggregation involves random molecular interac-
tions to initiate the formation of pathogenic structures
[33]. Therefore stochastic computer models can be es-
sential for examining the plausibility of alternative
mechanisms. To this end, we built a stochastic model of
turnover of Aβ42 (hereafter referred to as Aβ) to investi-
gate the effects of the degradation rate on Aβ levels and
specifically to discover whether a slower degradation
rate is itself sufficient to explain the increased level of
soluble Aβ and senile plaques seen in AD-affected
brains, a molecular phenomenon which is strongly
believed to underlie disruption of memory function
[16,18,34]. The potential clinical importance associated
with an intervention strategy to lower soluble Aβ levels
was demonstrated by Busche and others [35], who re-
cently provided evidence in support of the concept that
soluble Aβ induces neuronal dysfunction. This was
experimentally revealed by direct application of soluble
Aβ in wild-type mice, who then displayed pathological
neuronal hyperactivity within the hippocampus region.
This deficit was rescued through acute treatment with a
γ-secretase inhibitor, which reduced soluble Aβ levels.
Importantly, the authors observed that the selective in-
crease in neuronal hyperactivity preceded the formation
of plaques, to suggest that soluble species of Aβ may
underlie this functional neuronal impairment. We then
extended this model to include details of Aβ aggregation,
running simulations over long periods of simulated time
(up to 100 years) in order to examine the aggregation
process in human ageing. We used the model to com-
pare the plausibility of different candidate mechanisms
and, by varying key parameters in the model, to identify
which processes are most sensitive to modification and
might therefore be best to target in order to reduce the
burden of plaques.
Results
Model 1: Aβ turnover
A lower degradation rate of Aβ has only a small effect on
soluble levels of the protein but increases the probability
that monomers will exceed a critical threshold
This model showed that the difference in degradation rate
has only a small effect on soluble Aβ levels. Aβ does not
accumulate with time but just has a slightly higher level in
AD compared to normal (Figure 2). However, although
Figure 1 Cartoon of Aβ aggregation. Aβ monomers form dimers which then go on to form protofibrils and fibrils/plaques. Blue arrows
indicate the aggregation/disaggregation process. Black arrows are used to make labelling clearer. Note the possibility that APP and Aβ may
accumulate in mitochondria is also shown.
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levels of soluble Aβ do not accumulate with time, the
slightly higher levels of Aβ throughout life increase the
chance of aggregation. Due to stochastic effects, Aβ levels
occasionally increase above normal basal levels for short
periods of time and it may be possible that dimers are
formed during theses phases as shown by the intermittent
peaks in Figure 2. The first step in the aggregation process
is the formation of dimers, and since the probability of
dimer formation depends on the number of Aβ molecules,
we assume that dimer formation is unlikely to occur un-
less the number of Aβ molecules exceeds a threshold. For
example we could assume that the threshold is four and
then count the number of times that Aβ takes values that
are greater than four in each simulation. The model pre-
dicts that Aβ exceeds the threshold for a larger percentage
of times when the degradation rate is lower for either a
threshold of four or if the threshold is lowered to one
(Figure 3). In particular, when the threshold is one, there
is no overlap between the percentage of times that this
threshold is reached or exceeded between the normal and
AD degradation rates. Since we would expect plaques to
be rare when Aβ degradation rates are normal, our model
suggests that a threshold of one is biologically plausible.
Linear regression analysis showed that the slope of the
line was not significantly different from zero for normal
Aβ degradation when the threshold is four but it was
highly significant (p= 0.00019) for the AD degradation
rate (Figure 4A, B). There was no significant correlation
between mean Aβ levels and the percentage of times
that Aβ levels exceeded a threshold of four for normal
degradation rate (Pearson’s r = 0.10) or AD degradation
rate (Pearson’s r = 0.36). When the threshold was
reduced to one, the slope of the line was highly signifi-
cantly different from zero for both degradation rates
(p< 0.0001) and there was a strong positive correlation
between mean Aβ levels and the percentage of times
that the threshold was exceeded (normal degradation
rate, Pearson’s r = 0.87; AD degradation rate, Pearson’s
r = 0.84) (Figure 4C, D). The mean Aβ level was signifi-
cantly higher for the AD degradation rate compared to
the normal degradation, as seen by the lack of overlap in
the range of values (compare y-axis values in Figure 4A
and B or Figure 4C and D). The percentage of times that
Aβ exceeded any given threshold was also significantly
higher for the AD degradation rate (compare x-axis
values in Figure 4A and B or Figure 4C and D). There-
fore the lower degradation rate seen in AD may account
for the aggregation of Aβ in disease progression. To
examine this possibility we extended the model to in-
clude steps for Aβ aggregation.
Model 2: Aβ turnover and aggregation
Model 1 was extended by adding reactions for the for-
mation of dimers and aggregates, assuming that these
processes were reversible. We defined a plaque to be an
aggregate of size greater than 30 monomers as this was
the size at which according to the model output, an ag-
gregate had a very low probability of disaggregating
completely. Full details of our terminology are given in
the Methods section.
A B
Figure 2 Simulation output for model of Aβ turnover. The graph shows the level of Aβ versus time over a 100 year period in 6 typical runs.
A kdegAbeta= 2.1 e-5 s
-1 B kdegAbeta= 1.5 e-5 s
-1. The horizontal dashed lines correspond to the assumed threshold required for dimerisation to
occur.
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Decreased clearance of soluble Aβ leads to plaque formation
The model predicts that very few plaques are formed
when Aβ clearance is efficient (Figure 5A). If we assume
that the degradation of Aβ is lower throughout life then
the model predicts that plaques form at any age, with
just as many forming before the age of 60 as in later
years (Figure 5B), and there is a linear increase in the
number of cells associated with plaques with age
(Figure 5D, green curve). However, if we assume that Aβ
clearance gradually declines with age, the model predicts
that the majority of plaques form after age 60
(Figure 5C) and there is an exponential increase in the
number of cells associated with plaques with age
(Figure 5D, black curve). Therefore, it is much more
realistic to assume that the rate of Aβ clearance declines
with age in patients with a higher risk of AD, rather than
assuming impaired degradation from birth. It should be
noted that the graphs in Figure 5D show the percentage
of cells associated with plaques as a function of time and
that the actual size of plaque within each cell reach a
maximum size (see Figure 5C) and so the plaque burden
associated with particular sets of neurons reaches a plat-
eau rather continuing to increase in size.
We assumed that the rate of Aβ clearance declined with
age in AD due to the decline in neprilysin protein levels over
time. To see whether the model also predicted a change in
neprilysin activity with age, we added a dummy variable to
the model which counted each neprilysin-dependent Aβ
degradation reaction. A plot of this dummy variable versus
age is linear indicating that the reaction rate does not change
with time (not shown). The reaction contains both neprily-
sin and Aβ as reactants and so a decline in neprilysin with
time means that there must be an increase in the number of
Aβ monomers in order that the reaction rate remains con-
stant. Therefore our model predicts that the actual activity
per neprilysin molecule gradually increases with time due to
higher levels of monomers. However, despite the increase in
neprilysin activity, the levels of monomers are higher so that
there is a greater chance of dimers forming which may then
initiate the aggregation process.
Parameter scans for model 2
Dimerisation rate has the largest effect on the number of
plaques formed and the age of onset of plaque formation
We carried out parameter scans for each individual par-
ameter in Model 2 for the normal degradation rate, where
A B
C D
Figure 3 Histograms showing percentage of times that Aβ exceeds threshold for normal and AD degradation rates. A: threshold = 4,
kdegAbeta= 2.1 e-5 s
-1; B: threshold = 4, kdegAbeta= 1.5 e-5 s
-1; C: threshold= 1, kdegAbeta= 2.1 e-5 s
-1; D: threshold = 1, kdegAbeta= 1.5 e-5 s
-1. In each
case, 100 simulations were carried out and 500 time-points were recorded.
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we examined the effect on plaque formation. We considered
the average lag time (time to when plaques first appear),
plaque size and the percentage of cells associated with
plaques at different ages. We summarize the parameters
affecting each of these outcomes in Table 1. For each
parameter scan we carried out 500 simulations and cal-
culated the mean percentage of cells associated with
plaques at different time-points.
Varying kdimer
As the value of kdimer increases, the percentage of cells
associated with plaques increases as expected, since in-
creasing kdimer leads to more dimers and so an increased
probability of plaque formation. However, there was no
effect on plaque size since kdimer only affects the initial
step in plaque formation and not subsequent growth
which depends on the pool of monomers rather than
dimers. A plot of the percentage number of cells asso-
ciated with plaques at age 100 years versus kdimer is sig-
moidal so that very low values of kdimer lead to very low
numbers of plaques, followed by an exponential increase
and then a flattening off until eventually all cells are
associated with plaques (Figure 6A). It is not realistic
that all cells would be associated with plaques by age
100 years and so large values of kdimer are not biologic-
ally plausible. The parameter kdimer has a large effect on
the lag time with a negative correlation between kdimer
and median lag time. Varying the parameter kdedimer had
the opposite effect to varying kdimer (data not shown).
Varying kpf
Increasing the value of kpf leads to an increase in the
percentage of cells associated with plaques, up to a max-
imum of about 50% (Figure 6B). Even increasing kpf over
four orders of magnitudes did not result in all cells being
associated with plaques by age 100 years. This is because
the rate of plaque formation is dependent on the pool of
dimers and so can only increase if there are dimers avail-
able. Changing kpf has no effect on the size of plaques or
the lag time.
Varying parameters for plaque growth
The parameters which affect plaque growth are: kpg
(which affects the maximum rate) and kpghalf (which is
A B
C D
Figure 4 Linear regression analysis for mean Aβ levels versus percentage of times that Aβ exceeds two different thresholds for normal
and AD degradation rates. A: threshold = 4, kdegAbeta= 2.1 e-5 s
-1; B: threshold= 4, kdegAbeta= 1.5 e-5 s
-1; C: threshold = 1, kdegAbeta= 2.1 e-5 s
-1; D:
threshold= 1, kdegAbeta=1.5 e-5 s
-1. In each case, 100 simulations were carried out and 500 time-points were recorded.
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the plaque size at which the growth rate is 50% of the
maximum rate). The rate of growth also depends on the
plaque size and the availability of Aβ monomers. The
model predicts that increasing kpg initially leads to an in-
crease in the percentage of cells associated with plaques
but reaches a maximum of just over 12% and then there
is a sharp decline to about 10% which remains fairly
constant with further increases of the parameter
(Figure 6C). However, this behaviour is due to stochastic
effects as only small numbers of cells developed an asso-
ciation with plaques, as can be seen by the 95% confi-
dence interval (CI) error bars. Overall, the effect of
increasing kpg on the number of affected cells is small
since if plaques are not formed in the first place, they
cannot grow. As expected increasing the value of kpg
leads to larger plaques and has no effect on the lag time.
Increasing the value of kpghalf reduces the aggregation
rate and so the number of plaques decreases, but there
is no effect on plaque size.
Varying kdisagg
Increasing the rate of disaggregation kdisagg has no effect
on the percentage of cells associated with plaques or the
lag time. However, increasing this parameter has a large
negative effect on plaque size. This is not surprising as
disaggregation removes monomers from the plaques but
is not involved in the actual formation of plaques.
A B
C D
Figure 5 Output from 100 runs for different Aβ degradation rates. A-C Plots of plaques versus age from 100 simulated cells. A kdeg= 2.1e-5,
B kdeg =1.5e-5, C kdeg decreases linearly with age, D Plot of percentage of simulated cells associated with plaques versus age for each of the three
Aβ degradation rates shown in A-C.
Table 1 Effect of increasing parameter values on model
outputs for normal Aβ degradation rate (Model 2)
Parameter Number of
plaques (%)
Plaque size Lag time
kdimer Increases to
max of 100
No effect Decreases
kdedimer Decreases No effect Increases
kpf Increases to
max of ~50
No effect No effect
kpg Small effect Increases No effect
kpghalf Small effect No effect Slight decrease
for large values
kdisagg No effect Decreases Increase at
high values
kdegNep Increases Increases Decreases
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Varying rate of decline of neprilysin
Increasing the rate at which neprilysin declines leads to
an increase in both the number and size of plaques and
also decreased the lag time (Figure 7, Table 1). This is
because the levels of neprilysin affect Aβ degradation so
that if levels of neprilysin decline more rapidly, Aβ deg-
radation is impaired at an earlier age.
Addition of antibodies against Aβ dimers
Model predicts that early interventions have largest
benefits, although late interventions are also beneficial
To mimic the effect of adding antibodies against Aβ
dimers we added to the model the molecular species
named “antiAbDim”, which represents an antibody that
binds to Aβ dimers [20,36]. We added two reactions: one
for the binding of antiAbDim to AbDim, and another for
the continued addition of antiAbDim. We assumed that
initially the level of antiAbDim=0, and that no production
of antibodies takes place. In order to mimic the injection
of antibodies at different ages, we added an SBML event
structure to the model which set the level of antiAbDim
to 1000 and the parameter for continued addition of anti-
body to 1.0e-7 s-1 at different time-points during the simu-
lation. We simulated the effect of adding antibodies at age
50, 60, 70 and 80 years to examine at which age the model
predicts antibody treatment would be most effective. We
also simulated the addition of antibodies at age one year
to examine whether the model would predict that vaccin-
ating babies with Down’s syndrome would prevent the ac-
cumulation of plaques at early ages. Importantly, our
model predicts that immunotherapy is much more benefi-
cial if delivered at an early age while plaque levels are still
low, but that immunization delivered even at later ages is
still beneficial (Figure 8A). It is particularly noteworthy
that immunization at one year of age completely prevents
the accumulation of plaques with age and suggests a po-
tential therapy to prevent dementia in Down’s syndrome
affected patients.
A B
C D
Figure 6 Effect of varying parameter values on plaque formation. A kdimer, B kpf, C kpg, D kpghalf. Each point shows the percentage number of
cells associated with plaques at age 100 years from 500 simulations. The error bars show 95% confidence intervals for the percentages. The
dashed vertical line indicates the default parameter value. In B the x-axis is plotted on a log scale as the parameter values were varied over four
orders of magnitude. In A and C the x-axis is plotted on a log scale as the parameter values were not linearly spaced.
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Addition of antibodies against Aβ monomers
Model predictions suggest that this intervention may be
less effective than antibodies against Aβ dimers
Another therapeutic approach which is currently under
consideration is the use of antibodies against Aβ mono-
mers [[37], reviewed by[38]]. We do not believe that this
approach will be as effective as antibodies against dimers
for two important reasons. Firstly, it has been established
that dimers are toxic species but there is no clear evidence
that monomers have in themselves a pathologic role.
Secondly, monomers may well have a functional role and
so the use of antibodies against them may have detrimen-
tal effects. However, this approach could prevent the for-
mation of dimers and hence reduce plaque formation and
so it is of interest to use the model to make predictions
about the outcomes of such a procedure and to compare
the efficiency of preventing plaque formation using anti-
bodies against monomers and dimers. We used the same
method as for antibodies against dimers except we
replaced antiAbDim with a molecular species named anti-
AbMon which we assumed could bind to monomers and
so prevent the monomers from forming dimers or being
sequestered into plaques. Interestingly our model pre-
dicted that using antibodies against monomers requires
that the addition of antibodies is two orders of magnitude
higher than for dimers in order to reduce the level of pla-
ques to those shown in Figure 8. This is because Aβ
monomers are continually being produced and so a large
number of antibodies are required to prevent any dimer-
isation taking place and to prevent the sequestering of
monomers into aggregates. Our model also predicted that
if the addition of antibodies against monomers was carried
out at age 70 or 80, there was an initial significant de-
crease in the number of cells associated with plaques
which was due to increased disaggregation. However, at
any age of administration the maximal effect was only
temporary as antibodies became bound to monomers de-
pleting the available pool (Figure 8B).
Inhibition of Aβ production
Model predicts that inhibition of Aβ production is less
effective than targeting dimers especially for interventions
at early ages
Interventions to decrease Aβ production, such as secretase
inhibitors, are also being tested [39]. Therefore it is also of
interest to use our model to mimic the action of such an
intervention by decreasing the rate of Aβ production. As
in the antibody simulations, we simulated the intervention
starting at different ages. The model predicts that a 25%
reduction in the production rate slows down the rate at
which plaques form but does not completely prevent the
increase in plaque formation (Figure 8C). In particular, an
early intervention at age one year greatly reduces the
Table 2 List of parameter values for Model 2
Parameter Description Value Comment
kprod Aβ production rate 1.86e-5 molecules s
-1 Value from Mawuenyega at al. 2010 [22]
kdeg Aβ degradation rate 2.10e-5 s
-1 Values from Mawuenyega et al. 2010 [22]
kdimer Aβ dimerisation rate 1.2e-7 molecules
-1 s-1 Chosen from global parameter scan
kdedimer Dissociation rate of dimers 8.5e-6 s
-1 Chosen from global parameter scan
kpf Formation rate of plaques 2.8e-6 molecules
-1 s-1 Value in range of 1 new aggregate per 5 days
(Lomakin et al., 1997) [13]
kpg Maximum rate of plaque growth 5.7e-3 s
-1 Approx 5 monomers per min (Lomakin et al. 1997) [13]
kpghalf Size of plaque at which growth rate is half of kpg 4.0 molecules Chosen from global parameter scan
kdisagg Rate of plaque disaggregation 5.4e-5 s
-1 Chosen from global parameter scan
kdegNep Neprilysin degradation rate 0.0 s
-1 Normal rate (neprilysin remains constant with age)
1.8e-10 s-1 Set so that neprilysin declines to about 700 by age 60 years.
Figure 7 Varying kdegNep. Each point shows the percentage number
of cells associated with plaques at age 100 years from 500 simulations.
The error bars show 95% confidence intervals for the percentages. The
dashed vertical line indicates the default parameter value.
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plaque burden but does not completely prevent it as was
seen in the immunization simulations (compare pink
curves in Figures 8A and 8C). Therefore our model pre-
dicts that interventions to reduce Aβ production may not
be sufficient to prevent plaque formation unless adminis-
tered at high doses and for prolonged time periods.
Model 3 plaques grow by addition of dimers
The hypothesis that plaques grow by addition of dimers is
not supported by our model
Model 2 was modified so that plaques grow by the
addition of dimers instead of monomers and so that dis-
aggregation of plaques releases dimers. As for Model 2,
A CB
Figure 8 Simulated interventions. A Simulated vaccination with antibodies against Aβ dimers at different ages. B Simulated vaccination with
antibodies against Aβ monomers at different ages. C Simulated inhibition of Aβ production by 25% at different ages. A-C Each point shows the
percentage number of cells associated with plaques at age 100 years from 2000 simulations. The error bars show 95% confidence intervals for the
percentages. Parameters used in A: kbinantiAbDim=1.0e-7s
-1, kprodantiAb=1.0 e-7s
-1; parameters used in B: kbinantiAbMon=1.0e-7s
-1, kprodantiAb=1.0 e-5s
-1.
A B
C D
Figure 9 Simulation results showing sensitivity of parameters for Model 3. A kdimer, B kpf, C kpg, D kpghalf. Each point shows the percentage
number of cells associated with plaques at age 100 years from 100 simulations. Dashed black lines indicate the default value of the parameter.
Red dashed line in B indicates where the rate of plaque formation is approximately equal to the rate of plaque growth.
Proctor et al. Molecular Neurodegeneration 2012, 7:32 Page 10 of 17
http://www.molecularneurodegeneration.com/content/7/1/32
we chose a parameter set such that very few plaques
form under normal Aβ clearance but that at least 25% of
cells are associated with plaques by age 100. The para-
meters in this model are much more sensitive to per-
turbation by small stochastic effects than in Model 2,
and the model predicts that varying all the parameters
apart from kpf, produces three distinct regions in the
plots of percentage cells associated with plaques versus
parameter value (Figure 9). These correspond to values
where firstly no cells develop association with plaques;
secondly all cells develop association with plaques; and
thirdly, an intermediate situation exists. For the param-
eter kdimer, the intermediate range is very small, showing
that this is a very sensitive parameter in this model.
When the parameter kpf is varied, a very different shape
to the plot emerges. Initially increasing kpf led to an in-
crease in the percentage of cells associated with plaques
but after a maximum of 35% was attained, any further
increases in kpf led to a reduction in plaque levels. This
behaviour may seem rather strange but is the result of
both plaque formation and plaque growth depending on
the availability of Aβ dimers in this model. If the rate of
plaque formation exceeds the rate of plaque growth, then
plaques keep forming, disaggregating and reforming but
they cannot grow and cannot reach the size at which
plaque growth becomes irreversible (dashed red line in
Figure 9B indicates value of kpf where rate of plaque
formation is approximately equal to rate of plaque
growth). Most of the parameters are very sensitive to
small changes with only small regions where just a pro-
portion of cells are associated with plaques as opposed
to all or none. This suggests that Model 3 is less likely
to be biologically plausible than Model 2. Therefore,
our models provide strong support for the current con-
sensus that plaque growth is mediated by monomers ra-
ther than dimers.
Discussion
We have shown how a modelling approach can be used
to address questions concerning the aggregation of
amyloid-beta in Alzheimer’s disease. For many readers,
this approach may be unfamiliar and some may consider
it premature and incomplete. However, we would like to
point out that this is exactly why this paper is both
timely and valuable. We developed a stochastic model
which could be simulated over long time periods to in-
vestigate the effects of Aβ turnover on the accumulation
of plaques with age. The model showed that dimers play
an essential role in seeding (or starting) the aggregation
process and that targeting Aβ dimers rather than mono-
mers is likely to be the best approach for future inter-
ventions. The motivation for the model was to examine
in detail the basic steps in the process of amyloid aggre-
gation and to use the model to make predictions about
the effects of proposed interventions. There are many
different hypotheses concerning the aggregation process
in AD and great efforts are being made to find effective
interventions. Modelling is a useful tool for testing ideas
and examining the effects of proposed interventions
being able to make predictions which can be tested ex-
perimentally. For example, our model predicted that very
early interventions could prevent the formation of aggre-
gates at later ages. This could be tested experimentally
in an animal model of AD and/or an animal model of
trisomy 21.
We kept the model as simple as possible and so all the
processes that are included in the model are essential to
reproduce the results shown here. Stochastic simulation
was necessary in order to investigate the cellular vari-
ability in plaque formation. Each simulation run repre-
sents the outcome for one brain cell and we carried out
500 simulations for each parameter set. The simulation
output for 500 cells usually contain cells that do not de-
velop any association with plaques over a 100-year
period (depending on the parameter set) and in cells
where plaques form, the time of formation is very vari-
able. Our models predict that dimerisation of Aβ, which
is the first step in the aggregation process, has a large ef-
fect on both the timing of plaque formation and the
probability of a plaque forming.
We used the model to examine the effects of
immunization against dimers by simulating the addition of
antibodies at different ages followed by continued
provision of antibodies. This more closely resembles pas-
sive immunization with continual provision of antibodies.
Ideally, a model of active immunization would be prefer-
able as this procedure would act much better clinically.
However, active immunization is a complicated process
and would require a more complex model than we have
attempted here. Although we used a simple method to
mimic the process, the findings are still valuable and show
that it would be worthwhile to modify the model for active
immunization. An important finding from the simulations
is that the use of antibodies against dimers could greatly
reduce plaque burden and that they would be much more
beneficial if used in mid-life rather than in old age, but
that benefit is provided even if administered at later ages
provided the patient did not already have a high burden of
plaques. An exciting possibility is the development of a
vaccine for babies with Down’s syndrome to prevent the
early onset of AD. The current model has focussed on the
role of amyloid plaques in AD although the actual role of
plaques in the disease process is still not clear. On the one
hand some studies have shown a lack of correlation be-
tween plaque burden and the duration or severity of dis-
ease [40,41]. Conversely, another study showed an
increase in plaques in the neocortex which correlated with
severity of dementia and the authors concluded that
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plaques are not a consistent feature of ageing [42]. Plaques
are found in regions of the brain that are affected in AD
and they are usually associated with neuronal processes
causing synaptic loss and so may disrupt communication
between neurons. However, the exact role of plaques in
synaptic loss is still not clear [43]. Support for the role of
plaques in AD comes from post-mortem studies of brain
specimens from participants in the Phase 2a active
immunization trial that there was a significant reduction
in amyloid pathology which correlated with an improve-
ment in neurite abnormalities in the hippocampus and an
amelioration of tau pathology [44]. Our model does not
currently include any pathogenic role for plaques, rather
we just used them as a measured outcome. A future devel-
opment of the model would be to extend it to include de-
tail of synaptic function and include possible mechanisms
for how this could be disrupted by plaques.
Our models investigated only the role of monomers
and dimers in the aggregation process but could be
extended to include further steps such as larger oligo-
mers and protofibrils. This could be achieved by adding
further species to the model and replacing the reaction
of two dimers forming a plaque with a series of reac-
tions. This would allow the model to be used to examine
the effects of interventions on soluble oligomers. Since
soluble oligomers may be more toxic than the fibrillar
form of amyloid, this would be very desirable in order to
use the model to test interventions prior to clinical trials.
However, it should be noted that this will make the
model more complex and slower to simulate, and we
would need further information on how the different
amyloid components adversely affect cellular processes.
As the model is encoded in SBML, any future develop-
ments will be straightforward. Although we focus here
on the role of amyloid in AD, we have previously mod-
elled the aggregation of both Aβ and tau in a more com-
plex model [29]. However, the previous model could
only be used to mimic cellular models of aggregation
over time periods of days rather than years due to the
greatly increased computational load. A potential com-
promise in future studies might be to take some of the
key steps involved in tau aggregation and add them to
the model of Aβ turnover and aggregation. We could
also extend the model to include microglia and then use
the model to examine the effect of immunotherapy
against amyloid plaques. Another important extension to
the model would be to add apolipoprotein E (APOE)
which exists as three different isoforms (APOE2, APOE3
and APOE4) with APOE4 being known to have a patho-
genic role in AD [45]. A particularly relevant role of
APOE in AD is that the APOE-lipoprotein binds to Aβ
and is involved in Aβ clearance. However APOE4 is less
efficient than the other isoforms in this role, which
could contribute to its pathogenicity [46]. Finally we
could extend the model to examine the interaction be-
tween protein aggregation and mitochondrial dysfunc-
tion in AD. For example we could add the interaction
between APP, Aβ and mitochondria (Figure 1) as there
is evidence that the accumulation of full-length APP and
Aβ in the mitochondrial compartment has a causative
role in impairing mitochondrial physiological functions
[47]. We could also use the model to examine other pos-
sible therapies such as promoting degradation of Aβ by
administering agents that enhance the activity of Aβ-
degrading enzymes [28]. Our model predicts that lower
levels of neprilysin leads to an increase in plaque forma-
tion and so our model supports that the use of such
therapies could be beneficial. We could use our model
to test this by simulating the addition of extra neprilysin
at different time-points. This might require inserting
more detail of the mechanisms involved in the decline in
neprilysin activity with age. This approach could also be
relevant for other diseases such as cerebral amyloid
angiopathy since it has recently been shown that neprily-
sin protects cerebrovascular smooth muscle cells against
Aβ induced degeneration [48].
Conclusions
Progressive ageing of populations around the world, has
been accompanied by alarming growth in the numbers of
patients diagnosed with AD and other dementia-like ill-
nesses. The large number of studies showing a correlation
between synaptotoxic amyloid species, synapse loss and
cognitive deterioration which clinically characterises AD
patients, strongly suggests that targeting abnormal levels
of Aβ in the brain might provide a potentially powerful
preventative strategy. Nevertheless, there remain import-
ant questions about how such interventions might act
upon the normal mechanisms for formation and degrad-
ation of protein aggregates within the brain. It is import-
ant to understand the kinetics of these processes, which
are significantly influenced by the actions of chance at the
levels of the underlying molecular interactions. By
employing stochastic mathematical modelling, the present
study served to provide evidence for the validity of follow-
ing such an approach. Moreover, Aß dimer formation was
highlighted as a particularly important contributing mo-
lecular element underlying AD pathology, in agreement
with recently published experimental studies. In conclu-
sion, the study served to provide better insight into the
kinetic processes underlying eventual fibril/plaque forma-
tion, which might help pinpoint where and at which time-
point in such processes is the most therapeutically
promising targets for therapeutic intervention.
Methods
We began by building a model of Aβ turnover, which
includes reactions for Aβ production and degradation
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but does not consider the aggregation process. The aim
of this model, which we refer to as Model 1, was to see
the effect of decreased clearance on levels of Aβ over
time. We then extended this model to include details of
Aβ aggregation (Model 2) to examine the effects of
decreased clearance of Aβ on the aggregation process.
We also examined a variation of Model 2 in which a dif-
ferent assumption was made concerning the growth of
plaques. Details of all three models are given below.
Model 1: Aβ production and degradation
This model contained just one molecular species, Abeta,
and two reactions, synthesis and degradation:
Source !
kprod
Abeta
Abeta !
kdeg
Sink
We used mass action kinetics which means that the rate
of a reaction is directly proportional to the number of
molecules (note that we use stochastic simulation; in a
deterministic model number of molecules would be
replaced by concentration) of each reactant raised to the
power of its stoichiometry. In the first reaction equation,
Source is a constant dummy variable and so this is a
zeroth-order reaction with a constant production rate
and kprod is the hazard of this reaction. The second reac-
tion equation is of first-order and the hazard of this re-
action is kdeg Abeta. Details of how the model was coded
and simulated are given later in the Methods section
under the heading “Tools used for model construction
and simulation”.
In order to simulate the model, we need to choose
values for the parameters and the initial amount of
Abeta. We used the measured Aβ production rate (kpro-
dAbeta= 1.86e-5 molecules s
-1) from Mawuenyega and
colleagues [22]. The degradation rate depends on the
concentration of Aβ in the cell (e.g. kdegAbeta * Abeta).
Therefore we need to know the steady state level of Aβ.
The concentration of Aβ42 was measured in CSF and
was found to be 500pg/ml for patients with normal Aβ
clearance rates [22] and gives no indication about the
level of soluble Aβ42 at the cell surface where it is pro-
duced. Usually, Aβ is rapidly cleared and therefore we
would expect the level of Aβ in the vicinity of the mem-
brane to be low, especially as APP is found throughout
the cellular membrane and is not localised to a particu-
lar position. Therefore we assume that the local level of
Aβ is initially given by Abeta = 1, and assume kdegAbeta=
2.1e-5 s-1 for the normal degradation rate and kdegAbeta=
1.5e-5 s-1 for the degradation rate in AD. The model
was simulated 500 times for a particular set of para-
meters over a time period of 100 years and the level of
Aβ was output to a file (500 time-points were chosen).
The results were analysed and plotted in R (Figures 1, 2,
3, 4).
Model 2: Aβ turnover and aggregation
We extended Model 1 to include the aggregation of Aβ.
To keep the extended model as simple as possible we
make the following assumptions.
1. Two Aβ monomers may interact to form a dimer.
2. Dimers may disassociate into two monomers.
3. Two dimers may interact to form a small aggregate.
4. Aggregates may grow by the addition of monomers
only (although we also consider growth by dimers in
Model 3).
5. Aggregates may disaggregate to release a monomer.
6. When aggregates reach a certain threshold size, they
continue to grow until they reach a maximum size.
Once the aggregate has passed the threshold size we
consider it to be a plaque.
7. Since the actual size of the threshold is not fixed,
i.e. it varies in a stochastic fashion, we do not have
separate species for small aggregates and plaques
and use the name AbP for all aggregates. Therefore,
in our model output analysis we assume that if AbP
is greater than a certain level then it is counted as a
plaque. We chose 30 for this threshold size as
plaques of this size, or larger, rarely completely
disaggregated.
Rate laws and parameter values
Parameters for Aβ turnover
We used the same values for Aβ production and degrad-
ation as in Model 1. However, once we added the aggre-
gation steps, we found that the model predicted plaques
could occur at early ages when we set the degradation
rate at the AD level. Originally we assumed that Aβ
clearance was impaired throughout life. However, with
this assumption it was not possible to find a parameter
set where levels of plaques are very low early in life but
increase only after the age of 60 years (Figure 5B). There
are 3 possible ways that we could modify the model to
provide more realistic output. Firstly, the parameters
which affect lag time could be adjusted. Secondly, fur-
ther steps could be added to the aggregation process
such as formation of trimers, oligomers and protofibrils,
in order to increase the lag time. Finally, we assumed
that the degradation rate for AD is lower than normal
throughout life but it is more likely that the rate declines
with age. There are no parameters in the model which
affect only lag time (discussed in further detail in the
Results section). We did not wish to add further com-
plexity to the model, so did not consider the second pos-
sibility. The assumption of a constant low degradation
rate is probably not correct since if this was the case,
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then we would expect to see cases of sporadic AD at
earlier ages. Therefore we chose to amend the model so
that the degradation rate declines with age. We added
one of the Aβ degrading enzymes to the model, namely
neprilysin, since it is known that its level decreases with
age. We assumed that the Aβ degradation rate depended
on the level of neprilysin and that the level of neprilysin
declined with age in AD. Therefore we needed an add-
itional parameter, kdegNep, for the degradation rate of
neprilysin. We chose the value for this so that neprilysin
values declined by about 30% by age 60 which resulted
in Aβ degradation rates similar to those observed in AD
patients at late ages.
Parameters for Aβ aggregation
We needed to include an additional five reactions and
six parameters to model the kinetics of Aβ aggregation.
These are shown in Tables 2 and 3 and described in
more detail below. In vitro experiments show that once
plaques start to form, they grow rapidly (within about 24
hours) and then stop growing, i.e. they reach a max-
imum size. Since Aβ is continually produced, this obser-
vation suggests that degradation of plaques takes place
so that the process is not irreversible and that at a cer-
tain size disaggregation balances plaque growth. It has
been shown that plaques have a porous structure and so
the rate of disaggregation is likely to be proportional to
the volume of the plaque [49]. Therefore, we use first
order mass action kinetics for disaggregation and as-
sume that the rate depends only on the size of the aggre-
gate. The rate of aggregate growth depends on the
availability of Aβ dimers (AbDim) and/or monomers
(Abeta). The rate law must also contain the species AbP
(aggregates) so that aggregates cannot grow unless AbP
is greater than zero (if AbP = 0, then the rate of aggre-
gate growth must also equal zero). However, the rate of
growth cannot depend linearly on aggregate size, other-
wise, the rate of growth would continue to increase and
plaques would keep growing (Figure 10, black line). In-
stead we assume that initially the rate of plaque growth
increases with plaque size but that it reaches a max-
imum rate (kpg) at a particular plaque size which is
determined by the parameter kpghalf (Figure 10, curved
lines). This can be achieved by using a Hill function so
that the rate law for plaque growth is given by;
Plaque growth rate ¼ kpgAbeta
AbP2
kpghalf 2 þ AbP2
! "
We classify aggregates containing more than 30 mono-
mers as plaques (i.e. AbP >30), as our model output shows
that once aggregates reach this size, they are unlikely to dis-
aggregate completely but continue to grow in size. There-
fore, our use of the term “plaque” incorporates all
aggregates of Aβ which have exceeded a critical threshold
Table 3 List of reactions for Model 2
Reaction id Reactants Products Kinetic rate law
AbetaProduction Source Abeta kprod
AbetaDegradation Abeta Sink kdeg Abeta (Normal rate)
kdeg Abeta * Nep (AD rate)
Dimerisation 2Abeta AbDim kdimer Abeta*(Abeta-1)*0.5
Dedimerisation AbDim 2Abeta kdedimer AbDim
PlaqueFormation AbDim AbP kpf AbDim*(AbDim-1)*0.5
PlaqueGrowth Abeta, AbP 2AbP kpg Abeta*(AbP
2/(kpghalf
2 +AbP2))
Disaggregation AbP Abeta kdisagg AbP
NeprilysinDegradation Nep Sink kdegNep*Nep
Figure 10 Rate of plaque growth versus plaque size for
different rate laws. The continuous line shows a mass action rate
law with parameter 0.0004 and shows that the aggregation rate
increases linearly with plaque size. The dashed and dotted lines
show a rate law with Hill kinetics and the effect of changing the
parameter which represents the level of plaques where the rate is
half the maximal value.
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size and have a high probability of forming the amyloid
deposits which are termed “plaques” in the disease state.
The rate of fibril formation and fibril growth has been
measured experimentally and it has been reported that
fibrils grow at a rate of 0.5 monomers per minute and that
new fibril nucleation takes place approximately once in 5
days per micelle [13,50]. We chose values for kpf and kpg
based on these measurements. We do not have data for
the rates of dimerisation, disassociation of dimers or disag-
gregation of plaques and so we used a global parameter
scan in order to find parameter sets which predict very
low levels of plaques before the age of 50 years and then a
gradual increase in the number of plaques up to age 100
years (the maximum age used in our simulations). In
addition, we assumed that the parameters need to satisfy
the condition that levels of plaques do not exceed 10% by
age 100 years when Aβ clearance is normal, but that for
impaired Aβ clearance, levels exceed 25% by the age of
100 calendar years. We do not have data on the percent-
age of cells associated with plaques in normal ageing and
AD, but these values seemed reasonable. In future, these
values may be measurable and then it would be possible
to fit parameter sets to clinical data.
Since we need to use stochastic simulation, it is not
practical to do a full global parameter scan. Instead we
used Latin hypercube sampling to generate 100 param-
eter sets. We assumed that the values of kprod and kdeg
are fixed, and constrained kpf and kpg to be within half
and twice the values given by experimental data [13].
The other parameter values were allowed to vary by two
orders of magnitude. Initially we did 10 simulations for
each parameter set for the normal Aβ clearance rate.
We eliminated any sets where more than 30% of the
simulated cells produced plaques by age 100. We chose
30% rather than 10% since we initially only carried out
10 simulations for each parameter set to save computer
time and did not want to eliminate sets which by chance
had a high proportion of plaques. We then carried out
100 simulations for all the retained sets (64 sets) for the
impaired Aβ clearance rate (kdeg declines with age) and
eliminated any sets which either produced less than 10%
of cells associated with plaques by age 100 or produced
too many plaques (more than 15%) before the age of 50
years. This resulted in 10 possible sets. We did further
simulation runs for all these sets and finally chose the
set which gave the best difference between plaque levels
for normal and decreased clearance of Aβ. Details of the
parameter sets used in this analysis are given in
Additional file 1. Full details of the reactions and para-
meters are given in Tables 2, 3, and 4. A diagram of the
network is shown in Figure 11.
Model 3: Aβ turnover and aggregation with plaque
growth via dimers
Although the current consensus holds that plaque growth
is via monomers, it cannot be ruled out that dimers pro-
vide the building blocks for such pathological aggregates
[51]. To examine this possibility, we changed the reactions
Table 4 List of species for Model 2
Species id Description Initial value
Abeta Aβ monomer 0
AbDim Aβ dimer 0
AbP Plaque 0
Nep Neprilysin 1000
2
A production
A degradation
Dimerisation
Disassociationof dimers
Plaque formation
Plaque growth
Plaque disaggregation
Key
Figure 11 Diagram of the network for Model 2.
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for plaque growth and disaggregation. This model was fit-
ted with different parameter values and did not receive
such extensive analysis as shown in Model 2. The para-
meters are much more sensitive in this model. Apart from
kpf all the parameters can take values that result in no cells
associated with plaques, all cells associated with plaques
or an intermediate level of plaques (Figure 9).
Tools used for model construction and simulation
The models are encoded in the Systems Biology Markup
Language (SBML), a computer-readable format for net-
work models [52]. The tool used to create the SBML code
was SBML short-hand which uses a Python script to con-
vert a short-hand version of SBML into the full code [53].
The code is available from the Biomodels database (Bio-
models ID: MODEL1202290000)[54,55] and is also pro-
vided in Additional file 2. The SBML model can be
imported in any software tool which has the facility for
stochastic simulation. The stochastic simulations were car-
ried out using the gillespie2 code (available from the
SBML website [56]), which is based on the Gillespie algo-
rithm [57]. Briefly, this algorithm uses random numbers
to simulate the time to the next event and to pick the re-
action that occurs at this time according to the reaction
hazard. The number of molecules of each species is
updated according to the reaction which occurred. The
procedure is repeated until the simulated time to the next
event exceeds the maximum time of the simulation. The
model results were analysed and plotted using the R statis-
tical package.
Statistical analyses
The slopes of the regression lines in Figure 4 were tested
for statistical significance using a student’s unpaired t-
test. The correlation between two variables was calcu-
lated using Pearson’s r statistic. The 95% confidence
interval error bars for the percentage of cells associated
with plaques were calculated using ±1.96 x s.e., where s.
e. = √(p(100-p)/N), p is the percentage and N is the
number of simulated cells. All calculations were carried
out in the R statistical package.
Additional files
Additional file 1: This file contains details of parameters used in
the global parameter scan for Model 2 showing how the best
parameter set was chosen.
Additional file 2: This file contains the SBML code for Model 2 with
Aβ degradation rate decreasing with time.
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